Last reviewed · How we verify

NCT06173089: REMOTE-HEART

REmote MOnitoring of paTiEnts witH pacEmaker or implAntable cardioverteR defibrillaTor

Status unknown Last updated 15 December 2023
What this trial tests

trial testing Remote monitoring in Heart Failure in 800 participants. Status unknown.

Timeline
30 January 2023
Primary endpoint
30 June 2025
30 August 2025

Quick facts

Lead sponsorSemmelweis University Heart and Vascular Center
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment800
Start date30 January 2023
Primary completion30 June 2025
Estimated completion30 August 2025
Sites1 location across Hungary

Drugs / interventions tested

Conditions studied

Sponsor

Semmelweis University Heart and Vascular Center

Who can join

Adults 18 to 100, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

However, the current guidelines recommend the use of remote monitoring (RM) in patients with cardiac implantable electronic devices (CIED) to reduce inappropriate shocks or early detection of atrial fibrillation, data is incomprehensive on the effectiveness of decreasing heart failure events or mortality in patients with heart failure and reduced ejection fraction (HFrEF). The only randomized trial, which proved the efficacy of RM on mortality was the IN-TIME trial, which used a strict protocol for detection and intervention of the heart failure events. The primary aim of this study is to optimize the use of remote monitoring system in HFrEF patients already implanted an implantable cardiac defibrillator (ICD) or a cardiac resynchronization therapy (CRT). By creating a high-quality system with structured safety-net, which is able to use the data of remote monitoring messages and alerts of our patients, we can improve their outcome. The primary endpoint is the non-fatal heart failure event or all-cause mortality. Secondary outcomes include all-cause mortality, cardiovascular mortality, heart failure hospitalization, cardiovascular hospitalization, unscheduled visits, af burden, stroke, inappropriate shocks, quality of life, NYHA functional class. By using artificial intelligence-based methods, the optimal cut-off values of the previously, empirically used alert parameters will be validated or challenged. Additionally, cost-effectiveness to reduce the hospitalizations will be calculated. Due to this remote monitoring structured safety-net, these patients with severe heart failure can be treated more efficiently, safely and cost-effectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Remote monitoring

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Semmelweis University Heart and Vascular Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06173089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing